nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—ovarian follicle—ovarian cancer	0.0205	0.0586	CbGeAlD
Clodronate—SLC25A6—embryo—ovarian cancer	0.0169	0.0484	CbGeAlD
Clodronate—SLC25A5—myometrium—ovarian cancer	0.0153	0.0437	CbGeAlD
Clodronate—SLC25A5—embryo—ovarian cancer	0.0147	0.0421	CbGeAlD
Clodronate—SLC25A6—epithelium—ovarian cancer	0.0138	0.0395	CbGeAlD
Clodronate—SLC25A6—uterine cervix—ovarian cancer	0.0137	0.0391	CbGeAlD
Clodronate—SLC25A5—epithelium—ovarian cancer	0.012	0.0343	CbGeAlD
Clodronate—SLC25A5—uterine cervix—ovarian cancer	0.0119	0.034	CbGeAlD
Clodronate—SLC25A6—gonad—ovarian cancer	0.0115	0.0328	CbGeAlD
Clodronate—SLC25A6—uterus—ovarian cancer	0.0114	0.0326	CbGeAlD
Clodronate—SLC25A5—decidua—ovarian cancer	0.0113	0.0324	CbGeAlD
Clodronate—SLC25A5—endometrium—ovarian cancer	0.0108	0.0308	CbGeAlD
Clodronate—SLC25A4—decidua—ovarian cancer	0.0106	0.0304	CbGeAlD
Clodronate—SLC25A6—female reproductive system—ovarian cancer	0.0102	0.0293	CbGeAlD
Clodronate—SLC25A5—gonad—ovarian cancer	0.00998	0.0286	CbGeAlD
Clodronate—SLC25A5—uterus—ovarian cancer	0.00992	0.0284	CbGeAlD
Clodronate—SLC25A6—bone marrow—ovarian cancer	0.00967	0.0277	CbGeAlD
Clodronate—SLC25A4—gonad—ovarian cancer	0.00935	0.0268	CbGeAlD
Clodronate—SLC25A6—female gonad—ovarian cancer	0.00932	0.0267	CbGeAlD
Clodronate—SLC25A5—female reproductive system—ovarian cancer	0.00891	0.0255	CbGeAlD
Clodronate—SLC25A5—bone marrow—ovarian cancer	0.00842	0.0241	CbGeAlD
Clodronate—SLC25A4—female reproductive system—ovarian cancer	0.00835	0.0239	CbGeAlD
Clodronate—SLC25A6—testis—ovarian cancer	0.00827	0.0237	CbGeAlD
Clodronate—SLC25A5—female gonad—ovarian cancer	0.00811	0.0232	CbGeAlD
Clodronate—SLC25A5—vagina—ovarian cancer	0.00806	0.0231	CbGeAlD
Clodronate—SLC25A4—female gonad—ovarian cancer	0.0076	0.0217	CbGeAlD
Clodronate—SLC25A4—vagina—ovarian cancer	0.00756	0.0216	CbGeAlD
Clodronate—SLC25A5—testis—ovarian cancer	0.00719	0.0206	CbGeAlD
Clodronate—SLC25A4—testis—ovarian cancer	0.00674	0.0193	CbGeAlD
Clodronate—SLC25A6—lymph node—ovarian cancer	0.00599	0.0171	CbGeAlD
Clodronate—SLC25A5—lymph node—ovarian cancer	0.00521	0.0149	CbGeAlD
Clodronate—SLC25A4—lymph node—ovarian cancer	0.00489	0.014	CbGeAlD
Clodronate—Extravasation—Melphalan—ovarian cancer	0.00395	0.00892	CcSEcCtD
Clodronate—Anorexia—Altretamine—ovarian cancer	0.00378	0.00855	CcSEcCtD
Clodronate—Acute leukaemia—Doxorubicin—ovarian cancer	0.00375	0.00847	CcSEcCtD
Clodronate—Extravasation—Vinorelbine—ovarian cancer	0.00345	0.0078	CcSEcCtD
Clodronate—Decreased appetite—Altretamine—ovarian cancer	0.00345	0.00779	CcSEcCtD
Clodronate—Hepatocellular injury—Melphalan—ovarian cancer	0.00344	0.00779	CcSEcCtD
Clodronate—Hyperphosphataemia—Epirubicin—ovarian cancer	0.00339	0.00766	CcSEcCtD
Clodronate—Creatinine increased—Vinorelbine—ovarian cancer	0.00316	0.00714	CcSEcCtD
Clodronate—Hyperphosphataemia—Doxorubicin—ovarian cancer	0.00313	0.00708	CcSEcCtD
Clodronate—Renal failure acute—Chlorambucil—ovarian cancer	0.00311	0.00702	CcSEcCtD
Clodronate—Foetor hepaticus—Docetaxel—ovarian cancer	0.00302	0.00683	CcSEcCtD
Clodronate—PTGS2—myometrium—ovarian cancer	0.00288	0.00823	CbGeAlD
Clodronate—PTGS2—embryo—ovarian cancer	0.00277	0.00792	CbGeAlD
Clodronate—Infection—Carboplatin—ovarian cancer	0.00272	0.00615	CcSEcCtD
Clodronate—Renal failure acute—Melphalan—ovarian cancer	0.00271	0.00612	CcSEcCtD
Clodronate—Vomiting—Altretamine—ovarian cancer	0.00252	0.0057	CcSEcCtD
Clodronate—Liver disorder—Docetaxel—ovarian cancer	0.00252	0.00569	CcSEcCtD
Clodronate—Nausea—Altretamine—ovarian cancer	0.00236	0.00533	CcSEcCtD
Clodronate—Extravasation—Paclitaxel—ovarian cancer	0.00232	0.00524	CcSEcCtD
Clodronate—PTGS2—epithelium—ovarian cancer	0.00226	0.00646	CbGeAlD
Clodronate—Alanine aminotransferase increased—Topotecan—ovarian cancer	0.00225	0.00509	CcSEcCtD
Clodronate—PTGS2—uterine cervix—ovarian cancer	0.00224	0.00641	CbGeAlD
Clodronate—Cardiac failure—Vinorelbine—ovarian cancer	0.00224	0.00506	CcSEcCtD
Clodronate—Pneumonia—Chlorambucil—ovarian cancer	0.00222	0.00502	CcSEcCtD
Clodronate—Hypocalcaemia—Paclitaxel—ovarian cancer	0.00221	0.005	CcSEcCtD
Clodronate—Bronchospasm—Melphalan—ovarian cancer	0.00213	0.0048	CcSEcCtD
Clodronate—Local reaction—Epirubicin—ovarian cancer	0.00209	0.00472	CcSEcCtD
Clodronate—Blood creatinine increased—Vinorelbine—ovarian cancer	0.00205	0.00463	CcSEcCtD
Clodronate—PTGS2—endometrium—ovarian cancer	0.00203	0.0058	CbGeAlD
Clodronate—Pneumonia—Topotecan—ovarian cancer	0.00198	0.00447	CcSEcCtD
Clodronate—Extravasation—Docetaxel—ovarian cancer	0.00197	0.00444	CcSEcCtD
Clodronate—Wheezing—Paclitaxel—ovarian cancer	0.00197	0.00444	CcSEcCtD
Clodronate—Local reaction—Doxorubicin—ovarian cancer	0.00193	0.00437	CcSEcCtD
Clodronate—Dysphagia—Vinorelbine—ovarian cancer	0.00189	0.00427	CcSEcCtD
Clodronate—Serum creatinine increased—Epirubicin—ovarian cancer	0.00188	0.00425	CcSEcCtD
Clodronate—PTGS2—uterus—ovarian cancer	0.00187	0.00534	CbGeAlD
Clodronate—Oliguria—Docetaxel—ovarian cancer	0.00186	0.00421	CcSEcCtD
Clodronate—Bronchospasm—Vinorelbine—ovarian cancer	0.00186	0.0042	CcSEcCtD
Clodronate—Pharyngitis—Topotecan—ovarian cancer	0.00175	0.00396	CcSEcCtD
Clodronate—Serum creatinine increased—Doxorubicin—ovarian cancer	0.00174	0.00393	CcSEcCtD
Clodronate—Hepatocellular injury—Docetaxel—ovarian cancer	0.00172	0.00388	CcSEcCtD
Clodronate—Urinary tract disorder—Melphalan—ovarian cancer	0.00171	0.00386	CcSEcCtD
Clodronate—Connective tissue disorder—Melphalan—ovarian cancer	0.0017	0.00384	CcSEcCtD
Clodronate—Urethral disorder—Melphalan—ovarian cancer	0.0017	0.00383	CcSEcCtD
Clodronate—Pneumonia—Vinorelbine—ovarian cancer	0.00169	0.00383	CcSEcCtD
Clodronate—PTGS2—female reproductive system—ovarian cancer	0.00168	0.0048	CbGeAlD
Clodronate—Hypercalcaemia—Epirubicin—ovarian cancer	0.00167	0.00376	CcSEcCtD
Clodronate—Anaemia—Chlorambucil—ovarian cancer	0.0016	0.00361	CcSEcCtD
Clodronate—Mediastinal disorder—Topotecan—ovarian cancer	0.00159	0.0036	CcSEcCtD
Clodronate—Renal failure acute—Paclitaxel—ovarian cancer	0.00159	0.0036	CcSEcCtD
Clodronate—PTGS2—bone marrow—ovarian cancer	0.00158	0.00453	CbGeAlD
Clodronate—Angioedema—Chlorambucil—ovarian cancer	0.00158	0.00357	CcSEcCtD
Clodronate—Mediastinal disorder—Melphalan—ovarian cancer	0.00156	0.00352	CcSEcCtD
Clodronate—Renal impairment—Paclitaxel—ovarian cancer	0.00154	0.00349	CcSEcCtD
Clodronate—Hypercalcaemia—Doxorubicin—ovarian cancer	0.00154	0.00348	CcSEcCtD
Clodronate—PTGS2—female gonad—ovarian cancer	0.00153	0.00437	CbGeAlD
Clodronate—PTGS2—vagina—ovarian cancer	0.00152	0.00434	CbGeAlD
Clodronate—Cardiac failure—Paclitaxel—ovarian cancer	0.00151	0.0034	CcSEcCtD
Clodronate—Connective tissue disorder—Vinorelbine—ovarian cancer	0.00148	0.00336	CcSEcCtD
Clodronate—Anaemia—Topotecan—ovarian cancer	0.00142	0.00321	CcSEcCtD
Clodronate—Angioedema—Topotecan—ovarian cancer	0.0014	0.00318	CcSEcCtD
Clodronate—Infection—Chlorambucil—ovarian cancer	0.0014	0.00317	CcSEcCtD
Clodronate—Anaemia—Melphalan—ovarian cancer	0.00139	0.00315	CcSEcCtD
Clodronate—Blood creatinine increased—Paclitaxel—ovarian cancer	0.00138	0.00311	CcSEcCtD
Clodronate—Dehydration—Paclitaxel—ovarian cancer	0.00137	0.00309	CcSEcCtD
Clodronate—Mediastinal disorder—Vinorelbine—ovarian cancer	0.00136	0.00308	CcSEcCtD
Clodronate—Neoplasm malignant—Epirubicin—ovarian cancer	0.00135	0.00306	CcSEcCtD
Clodronate—Anorexia—Chlorambucil—ovarian cancer	0.00134	0.00304	CcSEcCtD
Clodronate—Abdominal pain upper—Paclitaxel—ovarian cancer	0.00134	0.00303	CcSEcCtD
Clodronate—Extravasation—Epirubicin—ovarian cancer	0.00133	0.003	CcSEcCtD
Clodronate—Renal impairment—Docetaxel—ovarian cancer	0.00131	0.00296	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.0013	0.00294	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Paclitaxel—ovarian cancer	0.0013	0.00293	CcSEcCtD
Clodronate—Cardiac failure—Docetaxel—ovarian cancer	0.00128	0.00288	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00127	0.00288	CcSEcCtD
Clodronate—Dysphagia—Paclitaxel—ovarian cancer	0.00127	0.00287	CcSEcCtD
Clodronate—Hypocalcaemia—Epirubicin—ovarian cancer	0.00126	0.00286	CcSEcCtD
Clodronate—Oliguria—Epirubicin—ovarian cancer	0.00126	0.00284	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—ovarian cancer	0.00125	0.00283	CcSEcCtD
Clodronate—Infection—Topotecan—ovarian cancer	0.00125	0.00282	CcSEcCtD
Clodronate—Dyspepsia—Chlorambucil—ovarian cancer	0.00124	0.0028	CcSEcCtD
Clodronate—Extravasation—Doxorubicin—ovarian cancer	0.00123	0.00277	CcSEcCtD
Clodronate—Decreased appetite—Chlorambucil—ovarian cancer	0.00123	0.00277	CcSEcCtD
Clodronate—Infection—Melphalan—ovarian cancer	0.00122	0.00276	CcSEcCtD
Clodronate—Skin disorder—Topotecan—ovarian cancer	0.00122	0.00276	CcSEcCtD
Clodronate—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00122	0.00275	CcSEcCtD
Clodronate—Anaemia—Vinorelbine—ovarian cancer	0.00122	0.00275	CcSEcCtD
Clodronate—Creatinine increased—Epirubicin—ovarian cancer	0.00122	0.00275	CcSEcCtD
Clodronate—Angioedema—Vinorelbine—ovarian cancer	0.0012	0.00272	CcSEcCtD
Clodronate—Anorexia—Topotecan—ovarian cancer	0.0012	0.0027	CcSEcCtD
Clodronate—Skin disorder—Melphalan—ovarian cancer	0.00119	0.0027	CcSEcCtD
Clodronate—Anorexia—Melphalan—ovarian cancer	0.00117	0.00265	CcSEcCtD
Clodronate—Hypocalcaemia—Doxorubicin—ovarian cancer	0.00117	0.00264	CcSEcCtD
Clodronate—Oliguria—Doxorubicin—ovarian cancer	0.00116	0.00263	CcSEcCtD
Clodronate—Dehydration—Docetaxel—ovarian cancer	0.00116	0.00262	CcSEcCtD
Clodronate—Hepatocellular injury—Epirubicin—ovarian cancer	0.00116	0.00262	CcSEcCtD
Clodronate—Pneumonia—Paclitaxel—ovarian cancer	0.00114	0.00257	CcSEcCtD
Clodronate—Abdominal pain upper—Docetaxel—ovarian cancer	0.00114	0.00257	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—ovarian cancer	0.00112	0.00254	CcSEcCtD
Clodronate—Urticaria—Chlorambucil—ovarian cancer	0.00112	0.00253	CcSEcCtD
Clodronate—Dyspnoea—Topotecan—ovarian cancer	0.00112	0.00253	CcSEcCtD
Clodronate—Abdominal pain—Chlorambucil—ovarian cancer	0.00111	0.00252	CcSEcCtD
Clodronate—Renal failure—Paclitaxel—ovarian cancer	0.00111	0.00252	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00111	0.00251	CcSEcCtD
Clodronate—Dyspepsia—Topotecan—ovarian cancer	0.0011	0.0025	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.0011	0.00248	CcSEcCtD
Clodronate—Dyspnoea—Melphalan—ovarian cancer	0.0011	0.00248	CcSEcCtD
Clodronate—Decreased appetite—Topotecan—ovarian cancer	0.00109	0.00247	CcSEcCtD
Clodronate—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00108	0.00245	CcSEcCtD
Clodronate—Dyspepsia—Melphalan—ovarian cancer	0.00108	0.00244	CcSEcCtD
Clodronate—Dysphagia—Docetaxel—ovarian cancer	0.00108	0.00243	CcSEcCtD
Clodronate—Hepatocellular injury—Doxorubicin—ovarian cancer	0.00107	0.00242	CcSEcCtD
Clodronate—Decreased appetite—Melphalan—ovarian cancer	0.00107	0.00241	CcSEcCtD
Clodronate—Infection—Vinorelbine—ovarian cancer	0.00107	0.00241	CcSEcCtD
Clodronate—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00106	0.0024	CcSEcCtD
Clodronate—Bronchospasm—Docetaxel—ovarian cancer	0.00106	0.00239	CcSEcCtD
Clodronate—Skin disorder—Vinorelbine—ovarian cancer	0.00104	0.00236	CcSEcCtD
Clodronate—Anorexia—Vinorelbine—ovarian cancer	0.00102	0.00231	CcSEcCtD
Clodronate—Pharyngitis—Paclitaxel—ovarian cancer	0.00101	0.00228	CcSEcCtD
Clodronate—Urinary tract disorder—Paclitaxel—ovarian cancer	0.001	0.00227	CcSEcCtD
Clodronate—Connective tissue disorder—Paclitaxel—ovarian cancer	0.000999	0.00226	CcSEcCtD
Clodronate—Pruritus—Chlorambucil—ovarian cancer	0.000997	0.00225	CcSEcCtD
Clodronate—Urticaria—Topotecan—ovarian cancer	0.000997	0.00225	CcSEcCtD
Clodronate—Urethral disorder—Paclitaxel—ovarian cancer	0.000996	0.00225	CcSEcCtD
Clodronate—Abdominal pain—Topotecan—ovarian cancer	0.000992	0.00224	CcSEcCtD
Clodronate—PTGS2—lymph node—ovarian cancer	0.000982	0.00281	CbGeAlD
Clodronate—Urticaria—Melphalan—ovarian cancer	0.000976	0.00221	CcSEcCtD
Clodronate—Pneumonia—Docetaxel—ovarian cancer	0.000965	0.00218	CcSEcCtD
Clodronate—Diarrhoea—Chlorambucil—ovarian cancer	0.000964	0.00218	CcSEcCtD
Clodronate—Hepatic function abnormal—Epirubicin—ovarian cancer	0.000961	0.00217	CcSEcCtD
Clodronate—Dyspnoea—Vinorelbine—ovarian cancer	0.000957	0.00216	CcSEcCtD
Clodronate—Renal failure—Docetaxel—ovarian cancer	0.000943	0.00213	CcSEcCtD
Clodronate—Decreased appetite—Vinorelbine—ovarian cancer	0.000933	0.00211	CcSEcCtD
Clodronate—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.000927	0.00209	CcSEcCtD
Clodronate—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000916	0.00207	CcSEcCtD
Clodronate—Renal failure acute—Epirubicin—ovarian cancer	0.00091	0.00206	CcSEcCtD
Clodronate—Vomiting—Chlorambucil—ovarian cancer	0.000896	0.00203	CcSEcCtD
Clodronate—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.000889	0.00201	CcSEcCtD
Clodronate—Pruritus—Topotecan—ovarian cancer	0.000888	0.00201	CcSEcCtD
Clodronate—Renal impairment—Epirubicin—ovarian cancer	0.000882	0.00199	CcSEcCtD
Clodronate—Pruritus—Melphalan—ovarian cancer	0.000869	0.00197	CcSEcCtD
Clodronate—Cardiac failure—Epirubicin—ovarian cancer	0.000861	0.00195	CcSEcCtD
Clodronate—Diarrhoea—Topotecan—ovarian cancer	0.000859	0.00194	CcSEcCtD
Clodronate—Pharyngitis—Docetaxel—ovarian cancer	0.000855	0.00193	CcSEcCtD
Clodronate—Urticaria—Vinorelbine—ovarian cancer	0.000853	0.00193	CcSEcCtD
Clodronate—Urinary tract disorder—Docetaxel—ovarian cancer	0.000851	0.00192	CcSEcCtD
Clodronate—Abdominal pain—Vinorelbine—ovarian cancer	0.000849	0.00192	CcSEcCtD
Clodronate—Connective tissue disorder—Docetaxel—ovarian cancer	0.000846	0.00191	CcSEcCtD
Clodronate—Urethral disorder—Docetaxel—ovarian cancer	0.000844	0.00191	CcSEcCtD
Clodronate—Renal failure acute—Doxorubicin—ovarian cancer	0.000842	0.0019	CcSEcCtD
Clodronate—Diarrhoea—Melphalan—ovarian cancer	0.000841	0.0019	CcSEcCtD
Clodronate—Nausea—Chlorambucil—ovarian cancer	0.000837	0.00189	CcSEcCtD
Clodronate—Anaemia—Paclitaxel—ovarian cancer	0.000818	0.00185	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—ovarian cancer	0.000816	0.00185	CcSEcCtD
Clodronate—Angioedema—Paclitaxel—ovarian cancer	0.000808	0.00183	CcSEcCtD
Clodronate—Vomiting—Topotecan—ovarian cancer	0.000798	0.0018	CcSEcCtD
Clodronate—Cardiac failure—Doxorubicin—ovarian cancer	0.000796	0.0018	CcSEcCtD
Clodronate—Rash—Topotecan—ovarian cancer	0.000791	0.00179	CcSEcCtD
Clodronate—Dermatitis—Topotecan—ovarian cancer	0.00079	0.00179	CcSEcCtD
Clodronate—Blood creatinine increased—Epirubicin—ovarian cancer	0.000787	0.00178	CcSEcCtD
Clodronate—Vomiting—Melphalan—ovarian cancer	0.000781	0.00177	CcSEcCtD
Clodronate—Dehydration—Epirubicin—ovarian cancer	0.000781	0.00177	CcSEcCtD
Clodronate—Mediastinal disorder—Docetaxel—ovarian cancer	0.000776	0.00175	CcSEcCtD
Clodronate—Rash—Melphalan—ovarian cancer	0.000775	0.00175	CcSEcCtD
Clodronate—Dermatitis—Melphalan—ovarian cancer	0.000774	0.00175	CcSEcCtD
Clodronate—Abdominal pain upper—Epirubicin—ovarian cancer	0.000767	0.00173	CcSEcCtD
Clodronate—Pruritus—Vinorelbine—ovarian cancer	0.000759	0.00172	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000748	0.00169	CcSEcCtD
Clodronate—Nausea—Topotecan—ovarian cancer	0.000745	0.00168	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000741	0.00167	CcSEcCtD
Clodronate—Diarrhoea—Vinorelbine—ovarian cancer	0.000734	0.00166	CcSEcCtD
Clodronate—Nausea—Melphalan—ovarian cancer	0.00073	0.00165	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000728	0.00165	CcSEcCtD
Clodronate—Dysphagia—Epirubicin—ovarian cancer	0.000726	0.00164	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—ovarian cancer	0.000723	0.00163	CcSEcCtD
Clodronate—Infection—Paclitaxel—ovarian cancer	0.000717	0.00162	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—ovarian cancer	0.00071	0.0016	CcSEcCtD
Clodronate—Skin disorder—Paclitaxel—ovarian cancer	0.000701	0.00159	CcSEcCtD
Clodronate—Anaemia—Docetaxel—ovarian cancer	0.000693	0.00157	CcSEcCtD
Clodronate—Anorexia—Paclitaxel—ovarian cancer	0.000688	0.00156	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000685	0.00155	CcSEcCtD
Clodronate—Vomiting—Vinorelbine—ovarian cancer	0.000682	0.00154	CcSEcCtD
Clodronate—Rash—Vinorelbine—ovarian cancer	0.000677	0.00153	CcSEcCtD
Clodronate—Dermatitis—Vinorelbine—ovarian cancer	0.000676	0.00153	CcSEcCtD
Clodronate—Dysphagia—Doxorubicin—ovarian cancer	0.000672	0.00152	CcSEcCtD
Clodronate—Pneumonia—Epirubicin—ovarian cancer	0.000651	0.00147	CcSEcCtD
Clodronate—Dyspnoea—Paclitaxel—ovarian cancer	0.000644	0.00146	CcSEcCtD
Clodronate—Nausea—Vinorelbine—ovarian cancer	0.000638	0.00144	CcSEcCtD
Clodronate—Renal failure—Epirubicin—ovarian cancer	0.000636	0.00144	CcSEcCtD
Clodronate—Dyspepsia—Paclitaxel—ovarian cancer	0.000636	0.00144	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000634	0.00143	CcSEcCtD
Clodronate—Decreased appetite—Paclitaxel—ovarian cancer	0.000628	0.00142	CcSEcCtD
Clodronate—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000623	0.00141	CcSEcCtD
Clodronate—Infection—Docetaxel—ovarian cancer	0.000608	0.00137	CcSEcCtD
Clodronate—Pneumonia—Doxorubicin—ovarian cancer	0.000602	0.00136	CcSEcCtD
Clodronate—Skin disorder—Docetaxel—ovarian cancer	0.000594	0.00134	CcSEcCtD
Clodronate—Renal failure—Doxorubicin—ovarian cancer	0.000589	0.00133	CcSEcCtD
Clodronate—Anorexia—Docetaxel—ovarian cancer	0.000583	0.00132	CcSEcCtD
Clodronate—Pharyngitis—Epirubicin—ovarian cancer	0.000577	0.0013	CcSEcCtD
Clodronate—Urinary tract disorder—Epirubicin—ovarian cancer	0.000574	0.0013	CcSEcCtD
Clodronate—Urticaria—Paclitaxel—ovarian cancer	0.000574	0.0013	CcSEcCtD
Clodronate—Connective tissue disorder—Epirubicin—ovarian cancer	0.000571	0.00129	CcSEcCtD
Clodronate—Abdominal pain—Paclitaxel—ovarian cancer	0.000571	0.00129	CcSEcCtD
Clodronate—Urethral disorder—Epirubicin—ovarian cancer	0.000569	0.00129	CcSEcCtD
Clodronate—Dyspnoea—Docetaxel—ovarian cancer	0.000546	0.00123	CcSEcCtD
Clodronate—Dyspepsia—Docetaxel—ovarian cancer	0.000539	0.00122	CcSEcCtD
Clodronate—Pharyngitis—Doxorubicin—ovarian cancer	0.000534	0.00121	CcSEcCtD
Clodronate—Decreased appetite—Docetaxel—ovarian cancer	0.000532	0.0012	CcSEcCtD
Clodronate—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000531	0.0012	CcSEcCtD
Clodronate—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000528	0.00119	CcSEcCtD
Clodronate—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000528	0.00119	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—ovarian cancer	0.000527	0.00119	CcSEcCtD
Clodronate—Mediastinal disorder—Epirubicin—ovarian cancer	0.000524	0.00118	CcSEcCtD
Clodronate—Pruritus—Paclitaxel—ovarian cancer	0.000511	0.00115	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—GADD45A—ovarian cancer	0.000504	0.00242	CbGpPWpGaD
Clodronate—Diarrhoea—Paclitaxel—ovarian cancer	0.000494	0.00112	CcSEcCtD
Clodronate—SLC25A6—Disease—FASN—ovarian cancer	0.000493	0.00237	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—FASN—ovarian cancer	0.000493	0.00237	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PARP1—ovarian cancer	0.000491	0.00236	CbGpPWpGaD
Clodronate—PTGS2—Overview of nanoparticle effects—IL6—ovarian cancer	0.000486	0.00233	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—SLC5A5—ovarian cancer	0.000485	0.00233	CbGpPWpGaD
Clodronate—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000484	0.0011	CcSEcCtD
Clodronate—Abdominal pain—Docetaxel—ovarian cancer	0.000484	0.00109	CcSEcCtD
Clodronate—SLC25A5—Disease—PPP2R1A—ovarian cancer	0.000475	0.00228	CbGpPWpGaD
Clodronate—SLC25A6—Disease—SLC2A1—ovarian cancer	0.000468	0.00225	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—SLC2A1—ovarian cancer	0.000468	0.00225	CbGpPWpGaD
Clodronate—Anaemia—Epirubicin—ovarian cancer	0.000467	0.00106	CcSEcCtD
Clodronate—PTGS2—Selenium Micronutrient Network—SOD2—ovarian cancer	0.000466	0.00224	CbGpPWpGaD
Clodronate—SLC25A4—Disease—XIAP—ovarian cancer	0.000463	0.00222	CbGpPWpGaD
Clodronate—Vomiting—Paclitaxel—ovarian cancer	0.000459	0.00104	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—IL6—ovarian cancer	0.000456	0.00219	CbGpPWpGaD
Clodronate—Rash—Paclitaxel—ovarian cancer	0.000455	0.00103	CcSEcCtD
Clodronate—Dermatitis—Paclitaxel—ovarian cancer	0.000455	0.00103	CcSEcCtD
Clodronate—SLC25A4—Disease—SMARCA4—ovarian cancer	0.000451	0.00217	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CYP1B1—ovarian cancer	0.000449	0.00216	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EREG—ovarian cancer	0.00044	0.00211	CbGpPWpGaD
Clodronate—Pruritus—Docetaxel—ovarian cancer	0.000433	0.000979	CcSEcCtD
Clodronate—Anaemia—Doxorubicin—ovarian cancer	0.000433	0.000978	CcSEcCtD
Clodronate—Nausea—Paclitaxel—ovarian cancer	0.000429	0.000969	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000428	0.000967	CcSEcCtD
Clodronate—Diarrhoea—Docetaxel—ovarian cancer	0.000419	0.000947	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	0.000416	0.002	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—FASN—ovarian cancer	0.000413	0.00198	CbGpPWpGaD
Clodronate—Infection—Epirubicin—ovarian cancer	0.00041	0.000927	CcSEcCtD
Clodronate—SLC25A6—Metabolism—SLC5A5—ovarian cancer	0.000406	0.00195	CbGpPWpGaD
Clodronate—Skin disorder—Epirubicin—ovarian cancer	0.000401	0.000906	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	0.000399	0.00192	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PPP2R1A—ovarian cancer	0.000398	0.00191	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PPP2R1A—ovarian cancer	0.000398	0.00191	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000396	0.000894	CcSEcCtD
Clodronate—SLC25A4—Metabolism—YAP1—ovarian cancer	0.000395	0.0019	CbGpPWpGaD
Clodronate—Anorexia—Epirubicin—ovarian cancer	0.000393	0.000889	CcSEcCtD
Clodronate—SLC25A6—Metabolism—SLC2A1—ovarian cancer	0.000392	0.00189	CbGpPWpGaD
Clodronate—Vomiting—Docetaxel—ovarian cancer	0.000389	0.00088	CcSEcCtD
Clodronate—Rash—Docetaxel—ovarian cancer	0.000386	0.000872	CcSEcCtD
Clodronate—Dermatitis—Docetaxel—ovarian cancer	0.000385	0.000871	CcSEcCtD
Clodronate—SLC25A4—Disease—FASN—ovarian cancer	0.000385	0.00185	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—MMP2—ovarian cancer	0.000384	0.00184	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PARP1—ovarian cancer	0.000383	0.00184	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	0.000382	0.00183	CbGpPWpGaD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	0.000381	0.00183	CbGpPWpGaD
Clodronate—Infection—Doxorubicin—ovarian cancer	0.000379	0.000858	CcSEcCtD
Clodronate—SLC25A5—Disease—TERT—ovarian cancer	0.000378	0.00181	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—CYP1B1—ovarian cancer	0.000376	0.00181	CbGpPWpGaD
Clodronate—Skin disorder—Doxorubicin—ovarian cancer	0.000371	0.000839	CcSEcCtD
Clodronate—SLC25A5—Metabolism—ABCB1—ovarian cancer	0.00037	0.00178	CbGpPWpGaD
Clodronate—Dyspnoea—Epirubicin—ovarian cancer	0.000368	0.000832	CcSEcCtD
Clodronate—SLC25A4—Disease—SLC2A1—ovarian cancer	0.000366	0.00176	CbGpPWpGaD
Clodronate—Anorexia—Doxorubicin—ovarian cancer	0.000364	0.000823	CcSEcCtD
Clodronate—Nausea—Docetaxel—ovarian cancer	0.000363	0.000822	CcSEcCtD
Clodronate—Dyspepsia—Epirubicin—ovarian cancer	0.000363	0.000821	CcSEcCtD
Clodronate—SLC25A5—Metabolism—TYMS—ovarian cancer	0.000363	0.00174	CbGpPWpGaD
Clodronate—Decreased appetite—Epirubicin—ovarian cancer	0.000359	0.000811	CcSEcCtD
Clodronate—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000356	0.000806	CcSEcCtD
Clodronate—SLC25A5—Disease—CAV1—ovarian cancer	0.000349	0.00168	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	0.000346	0.00166	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000343	0.00165	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	0.000342	0.00164	CbGpPWpGaD
Clodronate—Dyspnoea—Doxorubicin—ovarian cancer	0.00034	0.00077	CcSEcCtD
Clodronate—Dyspepsia—Doxorubicin—ovarian cancer	0.000336	0.00076	CcSEcCtD
Clodronate—SLC25A6—Metabolism—PPP2R1A—ovarian cancer	0.000334	0.0016	CbGpPWpGaD
Clodronate—Decreased appetite—Doxorubicin—ovarian cancer	0.000332	0.000751	CcSEcCtD
Clodronate—SLC25A5—Disease—IL6ST—ovarian cancer	0.000331	0.00159	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00033	0.000745	CcSEcCtD
Clodronate—Urticaria—Epirubicin—ovarian cancer	0.000328	0.000741	CcSEcCtD
Clodronate—Abdominal pain—Epirubicin—ovarian cancer	0.000326	0.000738	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	0.000325	0.00156	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—FASN—ovarian cancer	0.000322	0.00155	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—CXCL8—ovarian cancer	0.000319	0.00153	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	0.000318	0.00153	CbGpPWpGaD
Clodronate—SLC25A5—Disease—APC—ovarian cancer	0.000318	0.00153	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—SLC5A5—ovarian cancer	0.000317	0.00152	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TERT—ovarian cancer	0.000316	0.00152	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000313	0.00151	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	0.000312	0.0015	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	0.000311	0.0015	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PPP2R1A—ovarian cancer	0.000311	0.00149	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—ABCB1—ovarian cancer	0.00031	0.00149	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—SLC2A1—ovarian cancer	0.000306	0.00147	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—TYMS—ovarian cancer	0.000304	0.00146	CbGpPWpGaD
Clodronate—Urticaria—Doxorubicin—ovarian cancer	0.000303	0.000686	CcSEcCtD
Clodronate—Abdominal pain—Doxorubicin—ovarian cancer	0.000302	0.000683	CcSEcCtD
Clodronate—SLC25A4—Metabolism of proteins—MMP2—ovarian cancer	0.0003	0.00144	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TLR4—ovarian cancer	0.000296	0.00142	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism of proteins—CTNNB1—ovarian cancer	0.000294	0.00141	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	0.000294	0.00141	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CYP1B1—ovarian cancer	0.000294	0.00141	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000293	0.00141	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CAV1—ovarian cancer	0.000293	0.00141	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CAV1—ovarian cancer	0.000292	0.00141	CbGpPWpGaD
Clodronate—Pruritus—Epirubicin—ovarian cancer	0.000292	0.00066	CcSEcCtD
Clodronate—Diarrhoea—Epirubicin—ovarian cancer	0.000282	0.000638	CcSEcCtD
Clodronate—SLC25A5—Disease—PIK3CD—ovarian cancer	0.00028	0.00134	CbGpPWpGaD
Clodronate—SLC25A6—Disease—IL6ST—ovarian cancer	0.000277	0.00133	CbGpPWpGaD
Clodronate—Pruritus—Doxorubicin—ovarian cancer	0.00027	0.000611	CcSEcCtD
Clodronate—PTGS2—Disease—HSD17B6—ovarian cancer	0.00027	0.0013	CbGpPWpGaD
Clodronate—SLC25A6—Disease—APC—ovarian cancer	0.000267	0.00128	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CG—ovarian cancer	0.000266	0.00128	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.000265	0.00128	CbGpPWpGaD
Clodronate—Vomiting—Epirubicin—ovarian cancer	0.000262	0.000593	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000262	0.00126	CbGpPWpGaD
Clodronate—Diarrhoea—Doxorubicin—ovarian cancer	0.000261	0.000591	CcSEcCtD
Clodronate—SLC25A4—Metabolism—PPP2R1A—ovarian cancer	0.00026	0.00125	CbGpPWpGaD
Clodronate—Rash—Epirubicin—ovarian cancer	0.00026	0.000588	CcSEcCtD
Clodronate—Dermatitis—Epirubicin—ovarian cancer	0.00026	0.000588	CcSEcCtD
Clodronate—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	0.000257	0.00124	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000257	0.00124	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000257	0.00124	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000252	0.00121	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	0.00025	0.0012	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CXCL8—ovarian cancer	0.000249	0.0012	CbGpPWpGaD
Clodronate—SLC25A5—Disease—ERBB2—ovarian cancer	0.000247	0.00119	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TERT—ovarian cancer	0.000247	0.00119	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	0.000245	0.00118	CbGpPWpGaD
Clodronate—Nausea—Epirubicin—ovarian cancer	0.000245	0.000554	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CAV1—ovarian cancer	0.000245	0.00118	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MTOR—ovarian cancer	0.000244	0.00117	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PIK3CB—ovarian cancer	0.000244	0.00117	CbGpPWpGaD
Clodronate—Vomiting—Doxorubicin—ovarian cancer	0.000243	0.000549	CcSEcCtD
Clodronate—SLC25A4—Metabolism—ABCB1—ovarian cancer	0.000242	0.00116	CbGpPWpGaD
Clodronate—Rash—Doxorubicin—ovarian cancer	0.000241	0.000544	CcSEcCtD
Clodronate—Dermatitis—Doxorubicin—ovarian cancer	0.000241	0.000544	CcSEcCtD
Clodronate—SLC25A4—Metabolism—TYMS—ovarian cancer	0.000237	0.00114	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CD—ovarian cancer	0.000234	0.00113	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CD—ovarian cancer	0.000234	0.00113	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism of proteins—CTNNB1—ovarian cancer	0.00023	0.0011	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDKN1B—ovarian cancer	0.000229	0.0011	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CAV1—ovarian cancer	0.000228	0.0011	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—ovarian cancer	0.000227	0.000513	CcSEcCtD
Clodronate—SLC25A6—Metabolism—PIK3CG—ovarian cancer	0.000223	0.00107	CbGpPWpGaD
Clodronate—SLC25A4—Disease—IL6ST—ovarian cancer	0.000217	0.00104	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CTNNB1—ovarian cancer	0.000216	0.00104	CbGpPWpGaD
Clodronate—PTGS2—Disease—CHMP4C—ovarian cancer	0.000216	0.00104	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	0.000211	0.00102	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTEN—ovarian cancer	0.000211	0.00101	CbGpPWpGaD
Clodronate—SLC25A4—Disease—APC—ovarian cancer	0.000208	0.001	CbGpPWpGaD
Clodronate—SLC25A6—Disease—ERBB2—ovarian cancer	0.000207	0.000995	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NME2—ovarian cancer	0.000207	0.000995	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CB—ovarian cancer	0.000204	0.000982	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MTOR—ovarian cancer	0.000204	0.000982	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CB—ovarian cancer	0.000204	0.000981	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	0.000201	0.000964	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	0.000197	0.000945	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CD—ovarian cancer	0.000196	0.000943	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.000196	0.000942	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	0.000196	0.000941	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	0.000192	0.000923	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDKN1B—ovarian cancer	0.000192	0.000921	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	0.000192	0.000921	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—CAV1—ovarian cancer	0.000191	0.00092	CbGpPWpGaD
Clodronate—SLC25A5—Disease—STAT3—ovarian cancer	0.000188	0.000905	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NRAS—ovarian cancer	0.000188	0.000903	CbGpPWpGaD
Clodronate—PTGS2—Disease—BCL9—ovarian cancer	0.000187	0.0009	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	0.000187	0.000898	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000185	0.000891	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CD—ovarian cancer	0.000183	0.000879	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	0.000182	0.000874	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	0.000181	0.000872	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CTNNB1—ovarian cancer	0.000181	0.00087	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MAPK3—ovarian cancer	0.00018	0.000865	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTEN—ovarian cancer	0.000177	0.000848	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTEN—ovarian cancer	0.000176	0.000848	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000176	0.000844	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MYC—ovarian cancer	0.000175	0.000841	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CG—ovarian cancer	0.000174	0.000838	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MAPK1—ovarian cancer	0.000171	0.000823	CbGpPWpGaD
Clodronate—SLC25A5—Disease—EGFR—ovarian cancer	0.000171	0.000823	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CB—ovarian cancer	0.000171	0.000822	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—ovarian cancer	0.000162	0.000777	CbGpPWpGaD
Clodronate—SLC25A4—Disease—ERBB2—ovarian cancer	0.000162	0.000777	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MTOR—ovarian cancer	0.000159	0.000766	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CB—ovarian cancer	0.000159	0.000766	CbGpPWpGaD
Clodronate—SLC25A6—Disease—STAT3—ovarian cancer	0.000158	0.000759	CbGpPWpGaD
Clodronate—SLC25A6—Disease—NRAS—ovarian cancer	0.000157	0.000757	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	0.000154	0.000743	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	0.000154	0.000741	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CD—ovarian cancer	0.000153	0.000736	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MAPK3—ovarian cancer	0.000151	0.000725	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	0.00015	0.00072	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CDKN1B—ovarian cancer	0.00015	0.000719	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PIK3CA—ovarian cancer	0.000149	0.000714	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTEN—ovarian cancer	0.000148	0.000711	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MYC—ovarian cancer	0.000147	0.000705	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	0.000147	0.000705	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	0.000147	0.000705	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000144	0.000692	CbGpPWpGaD
Clodronate—SLC25A6—Disease—MAPK1—ovarian cancer	0.000144	0.00069	CbGpPWpGaD
Clodronate—SLC25A6—Disease—EGFR—ovarian cancer	0.000143	0.00069	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000143	0.000688	CbGpPWpGaD
Clodronate—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	0.000142	0.000685	CbGpPWpGaD
Clodronate—SLC25A4—Disease—CTNNB1—ovarian cancer	0.000141	0.00068	CbGpPWpGaD
Clodronate—PTGS2—Disease—PPP1CC—ovarian cancer	0.000139	0.000669	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTEN—ovarian cancer	0.000138	0.000662	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HRAS—ovarian cancer	0.000137	0.000661	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—ovarian cancer	0.000136	0.000651	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CB—ovarian cancer	0.000134	0.000642	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYTB—ovarian cancer	0.000133	0.000641	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000133	0.00064	CbGpPWpGaD
Clodronate—SLC25A5—Disease—IL6—ovarian cancer	0.000132	0.000632	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000131	0.000628	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.00013	0.000626	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.000127	0.000611	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000126	0.000605	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PIK3CA—ovarian cancer	0.000125	0.000599	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PIK3CA—ovarian cancer	0.000124	0.000598	CbGpPWpGaD
Clodronate—SLC25A4—Disease—STAT3—ovarian cancer	0.000123	0.000592	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	0.000123	0.000592	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NRAS—ovarian cancer	0.000123	0.000591	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000123	0.00059	CbGpPWpGaD
Clodronate—SLC25A5—Disease—AKT1—ovarian cancer	0.000121	0.000583	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAPK3—ovarian cancer	0.000118	0.000566	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPP1CC—ovarian cancer	0.000117	0.00056	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—BRIP1—ovarian cancer	0.000117	0.00056	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTEN—ovarian cancer	0.000115	0.000555	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HRAS—ovarian cancer	0.000115	0.000554	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MYC—ovarian cancer	0.000115	0.00055	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	0.000113	0.000542	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MAPK1—ovarian cancer	0.000112	0.000538	CbGpPWpGaD
Clodronate—SLC25A4—Disease—EGFR—ovarian cancer	0.000112	0.000538	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	0.000111	0.000533	CbGpPWpGaD
Clodronate—SLC25A6—Disease—IL6—ovarian cancer	0.00011	0.00053	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—ovarian cancer	0.000106	0.000509	CbGpPWpGaD
Clodronate—PTGS2—Disease—HDAC6—ovarian cancer	0.000105	0.000507	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	0.000105	0.000504	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PIK3CA—ovarian cancer	0.000104	0.000501	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	0.000102	0.00049	CbGpPWpGaD
Clodronate—SLC25A6—Disease—AKT1—ovarian cancer	0.000102	0.000489	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKT1—ovarian cancer	0.000102	0.000489	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	9.97e-05	0.000479	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	9.97e-05	0.000479	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PIK3CA—ovarian cancer	9.72e-05	0.000467	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	9.42e-05	0.000453	CbGpPWpGaD
Clodronate—PTGS2—Disease—XIAP—ovarian cancer	9.15e-05	0.00044	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HRAS—ovarian cancer	8.99e-05	0.000432	CbGpPWpGaD
Clodronate—PTGS2—Disease—SMARCA4—ovarian cancer	8.91e-05	0.000428	CbGpPWpGaD
Clodronate—PTGS2—Disease—EREG—ovarian cancer	8.7e-05	0.000418	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	8.66e-05	0.000416	CbGpPWpGaD
Clodronate—SLC25A4—Disease—IL6—ovarian cancer	8.61e-05	0.000414	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—AKT1—ovarian cancer	8.52e-05	0.000409	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	8.49e-05	0.000408	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	8.37e-05	0.000402	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PIK3CA—ovarian cancer	8.14e-05	0.000391	CbGpPWpGaD
Clodronate—SLC25A4—Disease—AKT1—ovarian cancer	7.94e-05	0.000382	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—YAP1—ovarian cancer	7.82e-05	0.000376	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	7.74e-05	0.000372	CbGpPWpGaD
Clodronate—PTGS2—Disease—FASN—ovarian cancer	7.61e-05	0.000366	CbGpPWpGaD
Clodronate—PTGS2—Disease—PARP1—ovarian cancer	7.58e-05	0.000364	CbGpPWpGaD
Clodronate—PTGS2—Disease—SLC2A1—ovarian cancer	7.23e-05	0.000347	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	7.07e-05	0.00034	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	6.8e-05	0.000327	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—AKT1—ovarian cancer	6.65e-05	0.00032	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—FASN—ovarian cancer	6.37e-05	0.000306	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC5A5—ovarian cancer	6.27e-05	0.000301	CbGpPWpGaD
Clodronate—PTGS2—Disease—PPP2R1A—ovarian cancer	6.15e-05	0.000295	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC2A1—ovarian cancer	6.05e-05	0.000291	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	5.93e-05	0.000285	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CYP1B1—ovarian cancer	5.8e-05	0.000279	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPP2R1A—ovarian cancer	5.15e-05	0.000247	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.12e-05	0.000246	CbGpPWpGaD
Clodronate—PTGS2—Disease—TERT—ovarian cancer	4.88e-05	0.000235	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—ABCB1—ovarian cancer	4.78e-05	0.00023	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TYMS—ovarian cancer	4.69e-05	0.000226	CbGpPWpGaD
Clodronate—PTGS2—Disease—CAV1—ovarian cancer	4.52e-05	0.000217	CbGpPWpGaD
Clodronate—PTGS2—Disease—IL6ST—ovarian cancer	4.28e-05	0.000206	CbGpPWpGaD
Clodronate—PTGS2—Disease—APC—ovarian cancer	4.11e-05	0.000198	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CAV1—ovarian cancer	3.78e-05	0.000182	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CD—ovarian cancer	3.62e-05	0.000174	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.61e-05	0.000174	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CG—ovarian cancer	3.45e-05	0.000166	CbGpPWpGaD
Clodronate—PTGS2—Disease—ERBB2—ovarian cancer	3.19e-05	0.000154	CbGpPWpGaD
Clodronate—PTGS2—Disease—MTOR—ovarian cancer	3.15e-05	0.000152	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CB—ovarian cancer	3.15e-05	0.000152	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CD—ovarian cancer	3.03e-05	0.000146	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDKN1B—ovarian cancer	2.96e-05	0.000142	CbGpPWpGaD
Clodronate—PTGS2—Disease—CTNNB1—ovarian cancer	2.8e-05	0.000134	CbGpPWpGaD
Clodronate—PTGS2—Disease—PTEN—ovarian cancer	2.72e-05	0.000131	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CB—ovarian cancer	2.64e-05	0.000127	CbGpPWpGaD
Clodronate—PTGS2—Disease—STAT3—ovarian cancer	2.44e-05	0.000117	CbGpPWpGaD
Clodronate—PTGS2—Disease—NRAS—ovarian cancer	2.43e-05	0.000117	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAPK3—ovarian cancer	2.33e-05	0.000112	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTEN—ovarian cancer	2.28e-05	0.00011	CbGpPWpGaD
Clodronate—PTGS2—Disease—MYC—ovarian cancer	2.26e-05	0.000109	CbGpPWpGaD
Clodronate—PTGS2—Disease—MAPK1—ovarian cancer	2.21e-05	0.000106	CbGpPWpGaD
Clodronate—PTGS2—Disease—EGFR—ovarian cancer	2.21e-05	0.000106	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—ovarian cancer	2.09e-05	0.000101	CbGpPWpGaD
Clodronate—PTGS2—Disease—PIK3CA—ovarian cancer	1.92e-05	9.24e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—HRAS—ovarian cancer	1.78e-05	8.55e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—IL6—ovarian cancer	1.7e-05	8.18e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PIK3CA—ovarian cancer	1.61e-05	7.74e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKT1—ovarian cancer	1.57e-05	7.55e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKT1—ovarian cancer	1.31e-05	6.32e-05	CbGpPWpGaD
